MTAP is altered in 4.55% of pancreatic ductal adenocarcinoma patients [3].

MTAP is an inclusion criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MTAP status and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MTAP is altered in 1.88% of urothelial carcinoma patients [3].

MTAP is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MTAP status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MTAP is altered in 1.25% of gastric adenocarcinoma patients [3].

MTAP is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MTAP status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MTAP is altered in 1.06% of adenocarcinoma of the gastroesophageal junction patients [3].

MTAP is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains MTAP status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) [4].

MTAP is altered in 1.16% of malignant solid tumor patients [3].

MTAP is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains MTAP status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [4].

MTAP is altered in 0.87% of non-small cell lung carcinoma patients [3].

MTAP is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MTAP status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MTAP is altered in 0.75% of head and neck squamous cell carcinoma patients [3].

MTAP is an inclusion criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MTAP status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MTAP is altered in 1.38% of lymphoma patients [3].

MTAP is an inclusion criterion in 1 clinical trial for lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MTAP status and lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MTAP is altered in 0.17% of prostate carcinoma patients [3].

MTAP is an inclusion criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MTAP status and prostate carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].